{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:36:43Z","timestamp":1790807803598,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00520-024-08817-4","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T14:03:00Z","timestamp":1726236180000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prevalence and risks of intravenous chemotherapy-induced severe neutropenia in solid cancers: a multicenter retrospective cohort study on real-life data"],"prefix":"10.1007","volume":"32","author":[{"given":"Olivia","family":"Rohr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Priou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Chatellier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Babai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Gallien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9mi","family":"Flicoteaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Tournigand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Kempf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Assistance Publique \u2013H\u00f4pitaux de Paris (AP-HP) Cancer Group, a CRAB* project","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Lam\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Verdoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Galula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,13]]},"reference":[{"issue":"9","key":"8817_CR1","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1002\/cncr.20983","volume":"103","author":"V Caggiano","year":"2005","unstructured":"Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT (2005) Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103(9):1916\u20131924. https:\/\/doi.org\/10.1002\/cncr.20983","journal-title":"Cancer"},{"issue":"2","key":"8817_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.6004\/jnccn.2008.0012","volume":"6","author":"J Crawford","year":"2008","unstructured":"Crawford J et al (2008) Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 6(2):109\u2013118. https:\/\/doi.org\/10.6004\/jnccn.2008.0012","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"8817_CR3","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/ecc.12057","volume":"22","author":"L Jolis","year":"2013","unstructured":"Jolis L et al (2013) Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study. Eur J Cancer Care (Engl) 22(4):513\u2013521. https:\/\/doi.org\/10.1111\/ecc.12057","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"1","key":"8817_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JOP.2014.001492","volume":"11","author":"D Weycker","year":"2015","unstructured":"Weycker D, Li X, Edelsberg J, Barron R, Kartashov A, Xu H, Lyman GH (2015) Risk and consequences of chemotherapy-induced febrile neutropenia in patients with metastatic solid tumors. J Oncol Pract 11(1):47\u201354. https:\/\/doi.org\/10.1200\/JOP.2014.001492","journal-title":"J Oncol Pract"},{"issue":"10","key":"8817_CR5","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258\u20132266. https:\/\/doi.org\/10.1002\/cncr.21847","journal-title":"Cancer"},{"issue":"2","key":"8817_CR6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.11882","volume":"100","author":"J Crawford","year":"2004","unstructured":"Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100(2):228\u2013237. https:\/\/doi.org\/10.1002\/cncr.11882","journal-title":"Cancer"},{"issue":"1","key":"8817_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1365-2354.2007.00797.x","volume":"17","author":"S Khan","year":"2008","unstructured":"Khan S, Dhadda A, Fyfe D, Sundar S (2008) Impact of neutropenia on delivering planned chemotherapy for solid tumours. Eur J Cancer Care (Engl) 17(1):19\u201325. https:\/\/doi.org\/10.1111\/j.1365-2354.2007.00797.x","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"4","key":"8817_CR8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1080\/07357907.2023.2179064","volume":"41","author":"R Mohanlal","year":"2023","unstructured":"Mohanlal R, Ogenstad S, Lyman GH, Huang L, Blayney DW (2023) Grade 4 neutropenia frequency as a binary risk predictor for adverse clinical consequences of chemotherapy-induced neutropenia: a meta-analysis. Cancer Invest 41(4):369\u2013378. https:\/\/doi.org\/10.1080\/07357907.2023.2179064","journal-title":"Cancer Invest"},{"key":"8817_CR9","unstructured":"Nissen-Druey C (1989) Human recombinant hemopoietic growth factors G-CSF and GM-CSF: first results of clinical trials. Nouv Rev Fr Hematol 31(2):99\u2013101. Accessed: Mar. 03, 2023. [Online]. Available: https:\/\/pubmed.ncbi.nlm.nih.gov\/2475852\/"},{"issue":"2","key":"8817_CR10","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1016\/j.cllc.2017.10.013","volume":"19","author":"J Cupp","year":"2018","unstructured":"Cupp J, Culakova E, Poniewierski MS, Dale DC, Lyman GH, Crawford J (2018) Analysis of factors associated with in-hospital mortality in lung cancer chemotherapy patients with neutropenia. Clin Lung Cancer 19(2):e163\u2013e169. https:\/\/doi.org\/10.1016\/j.cllc.2017.10.013","journal-title":"Clin Lung Cancer"},{"issue":"8","key":"8817_CR11","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/oncolo\/oyac074","volume":"27","author":"R Boccia","year":"2022","unstructured":"Boccia R, Glaspy J, Crawford J, Aapro M (2022) Chemotherapy-induced neutropenia and febrile neutropenia in the US: a beast of burden that needs to be tamed? Oncologist 27(8):625\u2013636. https:\/\/doi.org\/10.1093\/oncolo\/oyac074","journal-title":"Oncologist"},{"issue":"October","key":"8817_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.critrevonc.2017.11.005","volume":"120","author":"Y Lalami","year":"2017","unstructured":"Lalami Y, Klastersky J (2017) Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: an overview about well-established and recently emerging clinical data. Crit Rev Oncol Hematol 120(October):163\u2013179. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.11.005","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"8817_CR13","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1515\/raon-2016-0011","volume":"50","author":"K Strojnik","year":"2016","unstructured":"Strojnik K, Mahkovic-Hergouth K, Novakovic BJ, Seruga B (2016) Outcome of severe infections in afebrile neutropenic cancer patients. Radiol Oncol 50(4):442\u2013448. https:\/\/doi.org\/10.1515\/raon-2016-0011","journal-title":"Radiol Oncol"},{"issue":"5","key":"8817_CR14","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/archinte.1975.00330050089015","volume":"135","author":"EA Sickles","year":"1975","unstructured":"Sickles EA, Greene WH, Wiernik PH (1975) Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 135(5):715\u2013719","journal-title":"Arch Intern Med"},{"issue":"6","key":"8817_CR15","doi-asserted-by":"publisher","first-page":"379","DOI":"10.14740\/wjon1530","volume":"13","author":"K Moro","year":"2022","unstructured":"Moro K et al (2022) Advanced stage is a risk for severe neutropenia in breast cancer patients undergoing neoadjuvant adriamycin\/cyclophosphamide\/docetaxel chemotherapy. World J Oncol 13(6):379\u2013386. https:\/\/doi.org\/10.14740\/wjon1530","journal-title":"World J Oncol"},{"key":"8817_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.lungcan.2020.01.004","volume":"141","author":"X Cao","year":"2020","unstructured":"Cao X et al (2020) Predicting risk of chemotherapy-induced severe neutropenia: a pooled analysis in individual patients data with advanced lung cancer. Lung Cancer 141:14\u201320. https:\/\/doi.org\/10.1016\/j.lungcan.2020.01.004","journal-title":"Lung Cancer"},{"key":"8817_CR17","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.2147\/CMAR.S302722","volume":"13","author":"W Zou","year":"2021","unstructured":"Zou W, Xu N-L (2021) Development and internal validation of a nomogram used to predict chemotherapy-induced neutropenia in non-small cell lung cancer patients: a retrospective cohort study. Cancer Manag Res 13:2797\u20132804. https:\/\/doi.org\/10.2147\/CMAR.S302722","journal-title":"Cancer Manag Res"},{"issue":"3","key":"8817_CR18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1093\/annonc\/mdj092","volume":"17","author":"Y Lalami","year":"2006","unstructured":"Lalami Y et al (2006) Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors\u202f? A retrospective analysis. Ann Oncol 17(3):507\u2013514. https:\/\/doi.org\/10.1093\/annonc\/mdj092","journal-title":"Ann Oncol"},{"issue":"3","key":"8817_CR19","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","volume":"90","author":"GH Lyman","year":"2014","unstructured":"Lyman GH, Abella E, Pettengell R (2014) Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol 90(3):190\u2013199. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.12.006","journal-title":"Crit Rev Oncol Hematol"},{"issue":"16","key":"8817_CR20","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","volume":"18","author":"J Klastersky","year":"2000","unstructured":"Klastersky J et al (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol Off J Am Soc Clin Oncol 18(16):3038\u20133051. https:\/\/doi.org\/10.1200\/JCO.2000.18.16.3038","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"40","key":"8817_CR21","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.11124\/jbisrir-2012-31","volume":"10","author":"YM Lee","year":"2012","unstructured":"Lee YM, Lang D, Lockwood C (2012) Prognostic factors for risk stratification of adult cancer patients with chemotherapy-induced febrile neutropenia: a systematic review and meta-analysis. JBI Libr Syst Rev 10(40):2593\u20132657. https:\/\/doi.org\/10.11124\/jbisrir-2012-31","journal-title":"JBI Libr Syst Rev"},{"key":"8817_CR22","doi-asserted-by":"publisher","unstructured":"J. Klastersky and M. Paesmans, (2013) The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 21(5):1487\u20131495. https:\/\/doi.org\/10.1007\/s00520-013-1758-y","DOI":"10.1007\/s00520-013-1758-y"},{"issue":"1","key":"8817_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/JOP.18.00269","volume":"15","author":"AJ Zimmer","year":"2019","unstructured":"Zimmer AJ, Freifeld AG (2019) Optimal management of neutropenic fever in patients with cancer. J Oncol Pract 15(1):19\u201324. https:\/\/doi.org\/10.1200\/JOP.18.00269","journal-title":"J Oncol Pract"},{"issue":"1","key":"8817_CR24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3816\/SCT.2005.n.023","volume":"3","author":"J Crawford","year":"2005","unstructured":"Crawford J, Glaspy JA, Stoller RG, Tomita DK, Vincent ME, McGuire BW, Ozer H (2005) Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia. Support Cancer Ther 3(1):36\u201346. https:\/\/doi.org\/10.3816\/SCT.2005.n.023","journal-title":"Support Cancer Ther"},{"issue":"17","key":"8817_CR25","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2147\/TCRM.S318370","volume":"7","author":"O Alshari","year":"2021","unstructured":"Alshari O, Al Zu\u2019bi YO, Al Sharie AH, Wafai FH, Aleshawi AJ, Atawneh FH, Obeidat HA, Daoud MN, Khrais MZ, Albals D, Tubaishat F (2021) Evaluating the prognostic role of monocytopenia in chemotherapy-induced febrile neutropenia patients treated with granulocyte colony-stimulating factor. Ther Clin Risk Manag 7(17):963\u2013973. https:\/\/doi.org\/10.2147\/TCRM.S318370","journal-title":"Ther Clin Risk Manag"},{"issue":"11","key":"8817_CR26","doi-asserted-by":"publisher","first-page":"e2133474","DOI":"10.1001\/jamanetworkopen.2021.33474","volume":"4","author":"C Wang","year":"2021","unstructured":"Wang C, Heldermon CD, Vouri SM et al (2021) Trends in use of granulocyte colony-stimulating factor following introduction of biosimilars among adults with cancer and commercial or medicare insurance from 2014 to 2019. JAMA Netw Open 4(11):e2133474. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.33474","journal-title":"JAMA Netw Open"},{"issue":"13","key":"8817_CR27","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1016\/j.ejca.2010.04.031","volume":"46","author":"C Falandry","year":"2010","unstructured":"Falandry C, Campone M, Cartron G, Guerin D, Freyer G (2010) Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines. Eur J Cancer 46(13):2389\u20132398. https:\/\/doi.org\/10.1016\/j.ejca.2010.04.031","journal-title":"Eur J Cancer"},{"issue":"1","key":"8817_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s15010-013-0525-9","volume":"42","author":"L Nesher","year":"2014","unstructured":"Nesher L, Rolston KV (2014) The current spectrum of infection in cancer patients with chemotherapy related neutropenia. Infection 42(1):5\u201313. https:\/\/doi.org\/10.1007\/s15010-013-0525-9","journal-title":"Infection"},{"issue":"3","key":"8817_CR29","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jemermed.2019.09.032","volume":"58","author":"W Marshall","year":"2020","unstructured":"Marshall W, Campbell G, Knight T, Al-Sayed T, Cooksley T (2020) Emergency ambulatory management of low-risk febrile neutropenia: multinational association for supportive care in cancer fits-real-world experience from a UK cancer center. J Emerg Med 58(3):444\u2013448. https:\/\/doi.org\/10.1016\/j.jemermed.2019.09.032","journal-title":"J Emerg Med"},{"issue":"12","key":"8817_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00520-023-08065-y","volume":"31","author":"E Forcano-Queralt","year":"2023","unstructured":"Forcano-Queralt E, Lemes-Quintana C, Orozco-Beltr\u00e1n D (2023) Ambulatory management of low-risk febrile neutropenia in adult oncological patients. Systematic review. Support Care Cancer 31(12):1\u201310. https:\/\/doi.org\/10.1007\/s00520-023-08065-y","journal-title":"Support Care Cancer"},{"issue":"2","key":"8817_CR31","doi-asserted-by":"publisher","first-page":"R68","DOI":"10.1186\/cc8972","volume":"14","author":"S Andr\u00e9","year":"2010","unstructured":"Andr\u00e9 S et al (2010) Febrile neutropenia in French emergency departments: results of a prospective multicentre survey. Crit Care 14(2):R68. https:\/\/doi.org\/10.1186\/cc8972","journal-title":"Crit Care"},{"issue":"12","key":"8817_CR32","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1001\/jamainternmed.2023.5961","volume":"183","author":"M Roussel","year":"2023","unstructured":"Roussel M et al (2023) Overnight stay in the emergency department and mortality in older patients. JAMA Intern Med 183(12):1378\u20131385. https:\/\/doi.org\/10.1001\/jamainternmed.2023.5961","journal-title":"JAMA Intern Med"},{"issue":"24","key":"8817_CR33","doi-asserted-by":"publisher","first-page":"E851","DOI":"10.1503\/cmaj.230719","volume":"195","author":"C Varner","year":"2023","unstructured":"Varner C (2023) Emergency departments are in crisis now and for the foreseeable future. C Can Med Assoc J 195(24):E851\u2013E885. https:\/\/doi.org\/10.1503\/cmaj.230719","journal-title":"C Can Med Assoc J"},{"issue":"9","key":"8817_CR34","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1002\/cam4.2955","volume":"9","author":"T Aagaard","year":"2020","unstructured":"Aagaard T, Reekie J, J\u00f8rgensen M, Roen A, Daugaard G, Specht L, Sengel\u00f8v H, Mocroft A, Lundgren J, Helleberg M (2020) Mortality and admission to intensive care units after febrile neutropenia in patients with cancer. Cancer Med 9(9):3033\u20133042. https:\/\/doi.org\/10.1002\/cam4.2955","journal-title":"Cancer Med"},{"issue":"10","key":"8817_CR35","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.3109\/00016489.2015.1060631","volume":"135","author":"T Sasaki","year":"2015","unstructured":"Sasaki T, Takenaka Y, Hayashi T, Yamamoto M, Cho H, Fukusumi T, Takemoto N, Hanamoto A, Yasui T, Nakahara S, Yamamoto Y, Mitani K, Inohara H (2015) Factors predicting severe infections during chemotherapy in head and neck cancer patients. Acta Otolaryngol 135(10):1086\u20131091. https:\/\/doi.org\/10.3109\/00016489.2015.1060631","journal-title":"Acta Otolaryngol"},{"issue":"8","key":"8817_CR36","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00520-010-0928-4","volume":"19","author":"S Ahn","year":"2011","unstructured":"Ahn S, Lee YS, Chun YH, Kwon IH, Kim W, Lim KS, Kim TW, Lee KH (2011) Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia. Support Care Cancer 19(8):1151\u20131158. https:\/\/doi.org\/10.1007\/s00520-010-0928-4","journal-title":"Support Care Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08817-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-08817-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08817-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T04:20:46Z","timestamp":1729311646000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-08817-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["8817"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-08817-4","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,13]]},"assertion":[{"value":"25 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The French Data Protection Agency (CNIL, Commission Nationale de l\u2019Informatique et des Libert\u00e9s) authorized the constitution of the APHP CDW on January 19, 2017 (approval n\u00b019800120). AP-HP declared to the CNIL a single commitment to comply to the national reference methodology MR-004 () governing the processing of personal data for the purposes of studies, evaluations or research of a public interest nature that do not involve the human person, in particular studies on the reuse of data. This study conforming to the MR-004 and being conducted using the AP-HP CDW was approved by the APHP Scientific and Ethics Committee (IRB00011591) (approval CSE 20-0055_COVONCO-AP) on May 15th, 2020. Only the data that is strictly necessary and relevant regarding the objectives of the research has been collected and processed during this project.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"657"}}